239 related articles for article (PubMed ID: 38658543)
21. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
[TBL] [Abstract][Full Text] [Related]
22. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
23. EZH2 methyltransferase and H3K27 methylation in breast cancer.
Yoo KH; Hennighausen L
Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
[TBL] [Abstract][Full Text] [Related]
24. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
25. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
26. Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma.
Kwok HS; Freedy AM; Siegenfeld AP; Morriss JW; Waterbury AL; Kissler SM; Liau BB
Nat Chem Biol; 2023 Sep; 19(9):1105-1115. PubMed ID: 36973442
[TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
28. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
[TBL] [Abstract][Full Text] [Related]
29. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
[TBL] [Abstract][Full Text] [Related]
30. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
31. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
[TBL] [Abstract][Full Text] [Related]
32. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
Hwang IJ; Park J; Seo SB
Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
[TBL] [Abstract][Full Text] [Related]
33. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
34. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
[TBL] [Abstract][Full Text] [Related]
35. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
[TBL] [Abstract][Full Text] [Related]
36. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
[TBL] [Abstract][Full Text] [Related]
37. A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis.
Guo P; Lim RC; Rajawasam K; Trinh T; Sun H; Zhang H
Elife; 2024 Feb; 13():. PubMed ID: 38346162
[TBL] [Abstract][Full Text] [Related]
38. Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.
Lee CH; Yu JR; Kumar S; Jin Y; LeRoy G; Bhanu N; Kaneko S; Garcia BA; Hamilton AD; Reinberg D
Mol Cell; 2018 May; 70(3):422-434.e6. PubMed ID: 29681499
[TBL] [Abstract][Full Text] [Related]
39. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
40. A model for transmission of the H3K27me3 epigenetic mark.
Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
